1. Introduction {#sec0005}
===============

Since the first reports of cases from the Hubei Province of China at the end of 2019, more than 80,000 cases of novel coronavirus disease 2019 (COVID-19) have been diagnosed in China and thousands of cases have been reported in all continents ([@bib0090]). Italy has been one of the most involved countries since the end of February 2020 ([@bib0045]).

The lung involvement and the clinical deterioration seen in severe cases have been associated with a substantial increase in the levels of pro-inflammatory cytokines and interleukins (IL-2, IL-6, IL-7, Il-10) and inflammatory markers (D-dimer, ferritin, and C-reactive protein), with pro-inflammatory cytokine levels proportional to the severity of lung disease ([@bib0020], [@bib0015], [@bib0040], [@bib0085]). This clinical condition resembles the inflammatory derangement seen in other scenarios, such as sepsis-induced macrophage activation syndrome (MAS) ([@bib0035]) or immune dysregulation characterized by low expression of human leukocyte antigen D related (HLA-DR) on CD14 monocytes ([@bib0055]).

Moreover, preliminary observations have shown favorable outcomes when the IL-6 receptor inhibitor tocilizumab was used to treat severe COVID-19 patients ([@bib0060]). However, the long half-life of tocilizumab and its limited availability in the clinical arena promote the investigation of other therapeutic options. Among these, the recombinant interleukin-1 receptor antagonist anakinra may be beneficial in reducing the inflammatory storm observed in severe COVID-19 cases. Anakinra has been commonly used in the treatment of rheumatologic conditions, but previous studies report its efficacy in reducing mortality in septic subjects with MAS ([@bib0050], [@bib0065]).

Of note, no specific antiviral therapy has been approved by randomized clinical trials at the moment, even though some antiviral compounds may be associated with clinical improvement as reported by a recent preliminary report of individuals receiving remdesivir on a compassionate-use basis ([@bib0030]).

2. Case description {#sec0010}
===================

On March 10, 2020, a 57-year-old man presented to the emergency department of our hospital with a 5-day history of sore throat, cough, and fever (maximal body temperature of 39 °C). The patient did not disclose any contact with COVID-19 patients. Apart from a history of tobacco smoke and a body mass index of 30.8 kg/m^2^, the patient was otherwise healthy.

As shown in [Table 1](#tbl0005){ref-type="table"} , a body temperature of 38.5 °C and oxygen saturation of 92% while breathing on a Venturi mask were reported at presentation. Laboratory results revealed lymphopenia, a slight elevation of C-reactive protein (CRP) and troponin I, while the electrocardiogram and the echocardiogram performed did not show any abnormalities. A high-resolution computed tomography (HRCT) of the thorax revealed multiple patchy ground-glass opacities in subpleural regions bilaterally, with apical signs of emphysema ([Fig. 1](#fig0005){ref-type="fig"} ). A pharyngeal swab specimen was obtained and sent for detection of SARS-CoV-2 by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) assay: this was reported back within 6 hours as positive. The patient was tested for other respiratory viruses by nucleic acid amplification test and for *Legionella pneumophila* and *Streptococcus pneumoniae* by urinary antigens, without any evidence of concurrent infection. The patient was admitted at an infectious diseases unit with health care workers following airborne and droplets precautions.Table 1Vital signs, laboratory tests and treatments during the hospital course.Table 1![](fx1_lrg.gif)[^1]Fig. 1(or Supplementary Material). High-resolution computed tomography scans of the thorax at hospital day 1, 10, 20 and 30. Day 1. Multiple patchy ground-glass opacities in bilateral subpleural areas, especially in the posterior segment of the upper lobe and in the lower right lobe. Some traction bronchiectasis. Emphysematous changes. Day 10. Diffuse bilateral increase of parenchymal consolidations, with substantial involvement of the lower lung fields. Day 20. Favorable radiographic evolution with reduction of parenchymal consolidation in the lower lobes. Day 30. Further reduction in extension of the areas of parenchymal consolidation. Ectasia of the vascular structures in interstitial fibrosis areas.Fig. 1

An on off-label treatment with lopinavir/ritonavir (400/100 mg every 12 h per os) and hydroxychloroquine (200 mg every 8 h per os) was started. Azithromycin (500 mg every 24 h per os) and ceftriaxone (2 g every 24 h intravenously) were empirically associated to the ongoing treatment. Despite this, the respiratory status of the patient further deteriorated, with oxygen saturation values dropping to 89% while on reservoir. During this time ventilatory support was offered to the patient, who repeatedly refused both non-invasive and invasive ventilation. A psychiatric evaluation did not disclose any conditions impairing the decision-making ability of the patient and the ethical committee of the hospital accepted the patient\'s decision to refuse ventilatory support.

On day 7 of hospitalization the patient\'s clinical condition appeared extremely critical: ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F) was 50. Fever, asthenia and anorexia worsened and an increase of inflammatory markers (CRP, D-dimer, and ferritin) was noted with a profound change in lipid distribution. Due to the evidence of inflammatory dysregulation and the unavailability of tocilizumab in our hospital, treatment with anakinra was introduced (100 mg every 6 h subcutaneously for seven days). The patient was screened for HBV and *Mycobacterium tuberculosis* infection: test results were negative. In addition, lopinavir/ritonavir was discontinued and the investigational antiviral remdesivir was started as compassionate use (loading dose 200 mg, followed by 100 mg every 24 h intravenously for seven days).

Progressive normalization of the body temperature was observed, with persistently critical respiratory function. Because of a concern of hospital-acquired pneumonia, on day 10 ceftriaxone and azithromycin were discontinued and treatment with linezolid (600 mg every 12 h intravenously) and piperacillin/tazobactam (4.5 g every 6 h intravenously) was started. Blood and urine cultures performed on day 10 yielded negative results.

In the following days, the patient became afebrile and inflammatory markers dropped. By day 16, a substantial improvement in the respiratory function of the patient was also noticed, with oxygen saturation levels of 92% while on Venturi mask. New HRCT scans showed a progressive reduction of the consolidative lesions previously noticed. Pharyngeal swab specimens for SARS-CoV-2 testing were collected on day 24 and were positive. On day 32, supplemental oxygen was discontinued, oxygen saturation was 93% while the patient was breathing ambient air and he was proposed for transition to subacute care.

3. Discussion {#sec0015}
=============

To the best of our knowledge, we report the first treatment with the IL-1 receptor antagonist anakinra and remdesivir of a severe COVID-19 case ([@bib0020], [@bib0015]). IL-1 is the apical pro-inflammatory mediator, inducing both its own production and the synthesis of several secondary inflammatory mediators, such as IL-6 ([@bib0070]). Due to the possible role of IL-1/IL-6 axis blockade in conditions resembling MAS, the critical status of our patient, and the shortage of tocilizumab in our institution, we considered the administration of anakinra, in association with the most promising available antiviral agent and with adequate anti-thrombotic therapy ([@bib0065], [@bib0075]). Indeed, another possible and even more frequent pathological mechanism seems to be immune dysregulation with a decrease in HLA-DR expression on CD14 monocytes and overproduction of tumor necrosis factor-α (TNF-α) and IL-6 ([@bib0025]). Although this process could not implicate the overexpression of IL-1, because it may not affect the expression of this interleukin ([@bib0025]), the prompt resolution of fever, the reduction of inflammatory markers, and the improvement in the respiratory function observed in our patient are suggestive of a potential positive effect of anakinra. Nevertheless, the long-lasting positive detection of SARS-CoV-2 on pharyngeal swab specimens did not preclude the clinical recovery of the patients. As described in previous reports, this may suggest a long viral shedding, despite clinical improvement or resolution of symptoms ([@bib0095]).

Moreover, even if no venous thromboembolism was detected on a chest CT angiogram with contrast performed at day 10 after admission, anti-thrombotic therapy was also added as shown in [Table 1](#tbl0005){ref-type="table"}, as this strategy was suggested by progressively available evidence, particularly in consideration of the increase of D-dimer levels ([@bib0080]).

The main adverse effects associated with the use of anakinra are injection site reactions and severe infections ([@bib0010], [@bib0050]). In our experience no injection site reaction was identified and the elevation of procalcitonin reported on day 7 preceded the administration of anakinra. Moreover, the progression of the lung consolidation detected on day 10 could be expression of ongoing viral infection and inflammation. Nonetheless, the short half-life of anakinra allows a very rapid interruption of its immunomodulatory effect, different from what is observed for long-acting agents, such as tocilizumab ([@bib0005]).

The present report has several limitations. First, IL-1 and IL-6 levels were not evaluated during the hospital stay of the patient due to logistic limitations in an already overwhelmed health system. Second, quantitation of SARS-CoV-2 viral loads were not performed, due to similar constrains. Finally, we cannot make any causal inference regarding the clinical improvement of our patient and the use of anakinra, because of the observational design of this report.

In conclusion, this report highlights the potential role of anakinra in the treatment of respiratory dysfunction in COVID-19 patients. Clinical trials are needed to assess safety and efficacy of this immunomodulatory agent.
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[^1]: P/F: ratio of arterial oxygen partial pressure to fractional inspired oxygen; QD: every 24 h; BID: every 12 h; TID: every 8 h; QID: every 6 h; LD: loading dose.
